De-extinction and species preservation through gene editing
Colossal Biosciences is using CRISPR gene editing and synthetic biology to pursue de-extinction of the woolly mammoth, thylacine, and dodo. Their work also advances conservation genetics and novel biotechnology applications. Valued at $10.2B, making it one of the most valuable biotech startups globally.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| Woolly Mammoth Project | De-extinction | Research | CRISPR multiplex editing |
| Thylacine Project | De-extinction | Research | CRISPR / Synthetic embryology |
| Dodo Project | De-extinction | Research | CRISPR / Avian gene editing |
Life Biosciences launched the first-ever human trial of epigenetic reprogramming in January 2026 — an AAV gene therapy that uses three Yamanaka factors to reverse aging in the eye. Here's the full story of the company, its science, and what it means for the future of longevity medicine.
From billion-dollar reprogramming ventures to canine longevity drugs, here are the biotech companies leading the charge against aging in 2026.